The Department of Health and Human Services has proposed that the new administration review about 2,400 regulations that affect tens of millions of Americans, on everything from Medicare benefits to prescription drug approvals. Those not analyzed within two years would become void.
Instead of taking on the expense of traditional health plans, some small businesses are setting up an “individual coverage health reimbursement arrangement” that allows them to give workers money to put toward comprehensive coverage on the individual insurance market. But consumer advocates are concerned they may shortchange some workers.
A Trump administration maneuver allows executives who are leading the federal effort to keep investments in drug companies that would benefit from the pandemic response.
COVID-19 is spreading rapidly around the U.S. even before Thanksgiving promises to accelerate the trend. There are two promising vaccine candidates, but because President Donald Trump still refuses to concede the election and is holding up the official transition, President-Elect Joe Biden and his team cannot access plans for distributing those vaccines. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
As coronavirus cases surge, state officials can’t afford to wait for a new president to take office before taking action. But some governors’ initiatives seem to be little more than policy tweaks or symbolic gestures.
A provision the Trump administration tucked into its final rule on health plan price transparency requires telling consumers what they will pay out-of-pocket for drugs and showing them what the plan paid.
Former Vice President Joe Biden is now the president-elect nearly everywhere but inside the Trump administration, where the president refuses to concede and has ordered officials not to begin a formal transition. That is a particular problem for health care as the COVID-19 pandemic surges. Meanwhile, there’s good news on the vaccine front, but it’s unlikely one will arrive by winter. And the ACA was back before the Supreme Court — again. Joanne Kenen of Politico, Stephanie Armour of The Wall Street Journal and Shefali Luthra of the 19th News join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
President-elect Joe Biden inherits a global health landscape changed by the Trump administration more than under any Republican president since Ronald Reagan.
The U.S. Supreme Court will hear arguments Tuesday in a case that could overturn the Affordable Care Act. California Attorney General Xavier Becerra, who is defending the law with the backing of more than 20 other states, told California Healthline that he predicts the justices will uphold it.
As the votes continue to be counted in the tight battle between President Donald Trump and former Vice President Joe Biden, the federal role in health care is at stake.
